Seliciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Seliciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seliciclib overview
Seliciclib (CYC-202) is under development for the treatment of rheumatoid arthritis, Cushing's disease. It is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor. It is developed based on genomic technology. It was also under development for the treatment of non-small cell lung cancer (NSCLC), cystic fibrosis, and nasopharyngeal cancer (NPC), coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and inflammation.
Cyclacel Pharmaceuticals overview
Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company primarily engaged in the development of innovative therapies. These therapies target various phases of cell cycle control for the treatment of cancer and other serious diseases. The company’s major products in development include fadraciclib, a dual inhibitor of cyclin dependent kinases (CDK), and CYC140, a polo-like kinase 1 inhibitor. The company collaborates with renowned cancer research organizations such as MD Anderson Cancer Center and Dana Farber Cancer Institute to enhance its clinical programs. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
For a complete picture of Seliciclib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
